

Supplemental Table 5. Key Characteristics of the 17 Clinical Trials Included in the Network Meta-Analysis

Study Registration Number	Intervention	Quantity	Age	Baseline CD4+, cells/ml (SD)	Baseline Viral Load, log10 RNA copies/ml (SD)	Viral Load <50 copies/ml at 48 weeks (r/n)	Viral Load <50 copies/ml at 96 weeks (r/n)	Change in CD4+ at 48 weeks	Change in CD4+ at 96 weeks	Any Adverse Events (r/n)	Drug-Related Adverse Events (r/n)	Serious Adverse Events (r/n)	Grade 3-4 adverse events (r/n)	Drug resistance (r/n)
NCT01797445	E/C/F/TAF	431	35(10.8)	414 (206.8)	4.53 (0.647)	392/431	362/431	225 (171.2)	274(184.0)	Not reported in the study	Not reported in the study	54/431	Not reported in the study	Not reported in the study
	E/C/F/TDF	435	36(10.9)	431 (226.8)	4.50 (0.690)	385/435	358/435	200 (162.5)	260(179.6)	Not reported in the study	Not reported in the study	68/435	Not reported in the study	Not reported in the study
NCT01780506	E/C/F/TAF	435	35 (10.0)	437 (223.7)	4.55 (0.682)	405/435	388/435	235 (183.1)	285(203.0)	Not reported in the study	Not reported in the study	73/435	Not reported in the study	Not reported in the study
	E/C/F/TDF	432	36 (10.5)	426 (212.3)	4.55 (0.674)	401/432	381/432	221 (178.9)	271(208.1)	Not reported in the study	Not reported in the study	65/432	Not reported in the study	Not reported in the study
NCT01497899	E/C/F/TAF	112	35 (11.3)	385	4.55	99/112	Not reported in the study	177 (144.1)	Not reported in the study	106/112	Not reported in the study	12/112	11/112	0/112
	E/C/F/TDF	58	37 (10.6)	397	4.58	51/58	Not reported in the study	204 (120.4)	Not reported in the study	55/58	Not reported in the study	3/58	3/58	2/58
NCT02607930	B/F/TAF	314	31(25–41)	443 (299-590)	4.42 (4.03–4.87)	290/314	276/314 (87.9)	235 (185.8)	287(SD207)	300/314	94/314	41/314	50/314(144week)	0
	ABC/DTG/3TC	315	32(26–40)	450 (324-608)	4.51 (4.04–4.87)	293/315	283/315	228 (188.7)	288(247)	304/315	132/315	53/315	50/315	0
NCT02831673	DTG/3TC	356	34.0(9.88)	465.5	Not reported in the study	320/356	299/356	222 (186.2)	267.3	Not reported in the study	Not reported in the study	37/356	Not reported in the study	Not reported in the study
	DTG/F/TDF	358	35.0(10.72)	457.6	Not reported in the study	333/358	319/358	217.7 (201.32)	253.9	Not reported in the study	Not reported in the study	38/358	Not reported in the study	Not reported in the study
NCT02831764	DTG/3TC	360	34.6(10.72)	Not reported in the study	Not reported in the study	335/360	317/360	225.7 (169.62)	272.0(10.83)	306/360	39/360	39/360	39/360	Not reported in the study
	DTG/F/TDF	359	34.4(10.35)	Not reported in the study	Not reported in the study	337/359	323/359	217.2 (188.15)	264.6(11.18)	309/359	47/359	47/359	49/359	Not reported in the study
NCT01263015	ABC/DTG/3TC	414	36.5(10.74)	Not reported in the study	Not reported in the study	364/414	319/414	267.5 (192.30)	322.6(205.35)	397/414	186/414	65/414	Not reported in the study	Not reported in the study
	EFV/F/TDF	419	36.4(10.43)	Not reported in the study	Not reported in the study	339/419	293/419	209.5 (164.37)	286.0(195.70)	418/419	286/419	60/419	Not reported in the study	Not reported in the study
NCT01095796	E/C/F/TDF	348	38(10.4)	391 (188.6)	4.73 (0.6)	305/348	293/348	239 (167.2)	295(213.3)	Not reported in the study	Not reported in the study	69/348	Not reported in the study	Not reported in the study
	EFV/F/TDF	352	38(10.6)	382 (170.2)	4.78 (0.6)	296/352	287/352	206 (153.4)	273(189.7)	Not reported in the study	Not reported in the study	50/352	Not reported in the study	Not reported in the study
NCT03547908	B/F/TAF	122	33(9.2)	282 (193.1)	4.66 (4.22–5.12)	113/119 (95.0)	104/119	200 (139.3)	261(161.6)	116/121	35/121	17/121	22/121(96week)	Not reported in the study
	DTG/F/TDF	122	33(9.4)	266 (194.3)	4.69 (4.26–5.04)	111/122	107/122	175 (124.7)	229(174.0)	117/122	34/122	16/122	21/122	Not reported in the study
NCT03122262	DTG/F/TAF	351	33±7.8	349±225.3	Not reported in the study	295/351	276/351	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study
	DTG/F/TDF	351	32±8.1	323±234.3	Not reported in the study	298/351	275/351	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study
	EFV/F/TDF	351	32±7.4	337±221.6	Not reported in the study	277/351	258/351	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study	Not reported in the study
NCT02397694	B/F/TAF	65	34(11.4)	471 (190.9)	4.39 (0.764)	63/65	Not reported in the study	258 (221.7)	Not reported in the study	55/65	Not reported in the study	4/65	0/65	Not reported in the study
	DTG/F/TAF	33	38(12.9)	507 (271.0)	4.38 (0.866)	31/33	Not reported in the study	188 (238.7)	Not reported in the study	22/33	Not reported in the study	0/33	0	Not reported in the study
NCT02607956	B/F/TAF	320	37 (12.3)	457 (255.3)	4.39 (0.730)	286/320	269/320	180 (166.2)	237(204.2)	291/320	71/320	64/320	54/320(144week)	0
	DTG/F/TAF	325	37 (11.6)	454 (231.5)	4.42 (0.669)	302/325	281	201 (165.9)	281(209.3)	300/325	95/325	46/325	43/325	0
NCT00869557	E/C/F/TDF	48	36(8.9)	394	4.59	44/48	Not reported in the study	240 (172.8)	Not reported in the study	Not reported in the study	22/48	2/48	2/48	Not reported in the study
	EFV/F/TDF	23	35(9.6)	394	4.59	19/23	Not reported in the study	166 (158.5)	Not reported in the study	Not reported in the study	13/23	1月23日	2/23	Not reported in the study
NCT00100048	RAL/XTC/TDF	160	35(19-55)	338 (191)	4.6 (0.6)	137/160	133/160	174 (138.75)	221 (158.1)	146/160	82/160	16/160	Not reported in the study	Not reported in the study
	EFV/3TC/TDF	38	35(22-54)	280 (154)	4.8 (0.5)	33/38	32/38	170 (136.91)	232 (159.7)	35/38	28/38	3/38	Not reported in the study	Not reported in the study
NCT01227824	ABC/DTG/3TC	411	37.3(9.19)	379.2 (178.32)	4.538 (0.7258)	361/411	332/411	238.9 (171.81)	Not reported in the study	Not reported in the study	177/411	41/411	Not reported in the study	Not reported in the study
	RAL/XTC/TDF	411	36.6(10.02)	374.3 (163.37)	4.599 (0.7048)	351/411	314/411	257.5 (178.69)	Not reported in the study	Not reported in the study	210/411	45/411	Not reported in the study	Not reported in the study
ChCTR1800019041	ANV/3TC/TDF	315	31.1±9.9	383±183	4.5±0.7	274/315	271/293	Not reported in the study	Not reported in the study	283/315	213/315	Not reported in the study	12/315	Not reported in the study
	EFV/3TC/TDF	314	30.1±8.8	378±185	4.5±0.7	288/314	Not reported in the study	115	Not reported in the study	300/314	287/314	Not reported in the study	43/314(96week)	Not reported in the study
ChCTR1900024611	LPV/r+3TC	99	29.8(7.83)	330 (263-400)	4.4 (3.8–4.7)	92/99	85/99	202.5	222.5	99/99	Not reported in the study	0	Not reported in the study	Not reported in the study
	EFV/3TC/TDF	97	31.1(8.39)	327 (264-384)	4.4 (4.0–4.7)	92/97	80/97 (82.5)	176.1	183.7	96/97	Not reported in the study	0	Not reported in the study	Not reported in the study

Explanation and Insights from Supplemental Table 5

1. Study Characteristics:

The studies encompass a variety of ART regimens, including INSTI-based, NNRTI-based, and PI-based treatments. Each study includes a diverse population of patients with varying baseline CD4 counts and viral loads.

2. Efficacy Outcomes:

Viral suppression rates at 48 and 96 weeks are consistently reported across the studies, with most INSTI-based regimens showing comparable or superior results to NNRTI- and PI-based regimens.

3. Safety Outcomes:

Adverse event data, including drug-related and serious adverse events, are included for most studies. This provides critical insights into the safety profiles of the interventions.

For cells where data is unavailable:

1.Data not reported in the original study.

2.Data unavailable for this particular outcome.